pramiracetam

pramiracetam Structure
pramiracetam structure
Common Name pramiracetam
CAS Number 68497-62-1 Molecular Weight 269.383
Density 1.0±0.1 g/cm3 Boiling Point 461.0±30.0 °C at 760 mmHg
Molecular Formula C14H27N3O2 Melting Point 47 °C
MSDS Chinese USA Flash Point 232.6±24.6 °C
Symbol GHS07
GHS07
Signal Word Warning

The effects of cholinergic drugs support an avoidance learning hypothesis of brief footshock-induced analgesia.

Neuropharmacology 25(10) , 1161-6, (1986)

Rats were tested for tail-flick responses and then immediately subjected to footshock for 30 sec. This procedure induced analgesia, i.e. prolonged the latency of the tail-flick response, which was maximal immediately after the shock and decayed to normal leve...

The memory-enhancing effects of the piracetam-like nootropics are dependent on experimental parameters.

Behav. Brain Res. 33(1) , 79-82, (1989)

The effects of the nootropic agent piracetam and its congeners oxiracetam, pramiracetam and aniracetam on the retention performance of mice in a passive-avoidance situation are dependent on the intensity of the foot-shock applied. This phenomenon is observed ...

Gas chromatographic assay of pramiracetam in human plasma using nitrogen specific detection.

J. Chromatogr. A. 274 , 346-9, (1983)

Pharmacokinetics of pramiracetam in healthy volunteers after oral administration.

Int. J. Clin. Pharmacol. Res. 12(3) , 129-32, (1992)

The pharmacokinetics of pramiracetam was assessed using an HPLC method after oral administration of two different formulations of 600 mg (a solution and a tablet) of pramiracetam to 11 fasting volunteers. The mean kinetic parameters were: t1 = 4.7 +/- 2.4 - 4...

Pramiracetam and epileptic after-discharges in young rats after hypoxia.

Act. Nerv. Super. (Praha.) 31(1) , 68-9, (1989)

Pharmacokinetics of oral pramiracetam in normal volunteers.

J. Clin. Pharmacol. 25(4) , 291-5, (1985)

The pharmacokinetics of pramiracetam, a new, investigational, cognition activator, were assessed in normal male volunteers as part of a clinical tolerance study. In a double-blind, randomized design, two groups of six subjects each received alternating placeb...

Systemic administration of pramiracetam increases nitric oxide synthase activity in the cerebral cortex of the rat.

Funct. Neurol. 10(3) , 151-5, (1995)

The effect of systemic administration of pramiracetam on neuronal type nitric oxide synthase (NOS) activity and NOS mRNA expression were studied in the hippocampus and cerebral cortex in rats. A dose of 300 mg/kg (i.p.) of this nootropic produced an approxima...

The action of pramiracetam on consequences of hypobaric hypoxia is only moderate.

Physiol. Res. 45(3) , 245-8, (1996)

The possible protective action of pramiracetam, a pyrrolidinone nootropic drug, against hypobaric hypoxia was studied in two age groups of immature rats with implanted electrodes. Epileptic afterdischarges induced by hippocampal stimulation were used as a mea...

Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam.

J. Med. Chem. 27(5) , 684-91, (1984)

A series of N-[(dialkylamino)alkyl]-2-oxo-1- pyrrolidineacetamides was synthesized. The title compounds reversed electroconvulsive shock (ECS) induced amnesia in mice when administered subsequent to the ECS treatment and were inactive in a general observation...

The effect of pramiracetam (CI-879) on the acquisition of a radial arm maze task.

Psychopharmacology 89(3) , 378-81, (1986)

The effect of the nootropic drug pramiracetam (CI-879) on acquisition of a radial arm maze task was examined in the rat. Two doses of pramiracetam (7.5 mg/kg and 15 mg/kg) were administered daily prior to testing for 7 weeks in a 16-arm radial maze in which n...